<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14841-bib-0014">
 <label>14</label>
 <mixed-citation publication-type="journal" id="cas14841-cit-0014">
  <string-name>
   <surname>Soeda</surname>
   <given-names>H</given-names>
  </string-name>, 
  <string-name>
   <surname>Shimodaira</surname>
   <given-names>H</given-names>
  </string-name>, 
  <string-name>
   <surname>Gamoh</surname>
   <given-names>M</given-names>
  </string-name>, et al. 
  <article-title>Phase II trial of cetuximab plus irinotecan for oxaliplatin‐ and irinotecan‐based chemotherapy‐refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T‐CORE0801)</article-title>. 
  <source xml:lang="en">Oncology</source>. 
  <year>2014</year>;
  <volume>87</volume>(
  <issue>1</issue>):
  <fpage>7</fpage>‐
  <lpage>20</lpage>.
 </mixed-citation>
</ref>
